Growth Response to Weekly Somapacitan Therapy in Children With GH Deficiency Is Related to GH Thresholds in GH Stimulation Testing
Patients with GHD in the ≤3 μg/L GH peak concentration group had greater HV and greater changes in height SDS and IGF-I SDS from baseline.
Authors
- Bradley S. Miller (ORCID: https://orcid.org/0000-0003-3663-5473)
- Majbritt Jeppesen
- Michael Højby Rasmussen (ORCID: https://orcid.org/0000-0002-2210-0366)
- Alberto Pietropoli (ORCID: https://orcid.org/0000-0003-0353-4334)
- Jun Mori (ORCID: https://orcid.org/0000-0002-1271-1577)
- Nicky Kelepouris (ORCID: https://orcid.org/0000-0003-2445-2338)
- Philippe Backeljauw (ORCID: https://orcid.org/0000-0003-2398-9520)
- Claudia Boettcher
Institutions
- University of Bern (CH)
- Cincinnati Children's Hospital Medical Center (US)
- University of Minnesota (US)
- Fairview Health Services (US)
- Novo Nordisk (Denmark) (DK)
- Osaka City General Hospital (JP)
- Novo Nordisk (United States) (US)
- Novo Nordisk (Switzerland) (CH)
- University of Cincinnati (US)
Publication Details
- Journal
- Journal of the Endocrine Society
- Published
- 2025-02-27
- DOI
- https://doi.org/10.1210/jendso/bvaf038
- Citations
- 1
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Novo Nordisk